Abstract
ABSTRACT
Objective: (1) To evaluate the serum Sclerostin concentration in patients with CKD who have not yet undergone dialysis from stage G3 to G5, compared with a control group of healthy people with normal renal function. (2) To evaluate the relationship between serum Sclerostin concentration and some related factors in patients with CKD.
Patients and methods: This is a cross-sectional descriptive study on 84 patients with CKD who have not yet undergone dialysis (including 32 patients with stage 3, 4 CKD and 52 patients with stage 5 CKD) at the Department of Nephrology - Musculoskeletal, Hue Central Hospital and 60 healthy people with normal kidney function regularly came for health check-ups at the Internal Medicine Clinic of Hue University of Medicine and Pharmacy from April 2023 to 2025.
Results: Our study was conducted on 84 non-dialyzed patients with chronic kidney disease (CKD) stages 3 to 5, including 32 patients in stages 3 and 4, and 52 patients in stage 5. The control group consisted of 60 healthy individuals with normal renal function. The mean serum sclerostin concentration in the control group was 359.52 ± 168.21 pg/mL. Serum sclerostin levels were significantly higher in the CKD group compared to controls (p < 0.05), with levels in the CKD stage 3–4 group recorded at 1090.63 ± 901.65 pg/mL and in the stage 5 group at 1464.26 ± 892.94 pg/mL. In our study, serum sclerostin levels were significantly higher in males than in females within the control group (p < 0.05) and in the CKD stage 5 group. Furthermore, serum sclerostin levels showed a statistically significant positive correlation with age in the CKD stage 3–4 group (p < 0.05). No statistically significant differences in serum sclerostin concentrations were observed between non-dialyzed CKD patients with or without hypertension or anemia.
Conclusion: Sclerostin is a glycoprotein produced by osteocytes that inhibits bone formation through the Wnt/β-catenin signaling pathway. In patients with CKD, serum sclerostin levels progressively increase with advancing stages of the disease. Our study demonstrated that in non-dialyzed CKD stage 3–5 patients, serum sclerostin levels were significantly higher than in healthy controls with normal renal function. According to our findings, serum sclerostin concentrations were higher in males than in females in both the control group and in patients with CKD stage 5, and levels tended to increase with age. However, no statistically significant differences in serum sclerostin levels were observed between non-dialyzed CKD patients with or without hypertension or anemia.
Keywords: Sclerostin, chronic kidney disease, CKD.
| Published | 2025-12-30 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 15 No. 6 (2025) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2025.6.728 | |
| Keywords | Sclerostin, CKD |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Hue Journal of Medicine and Pharmacy
van Bezooijen RL, Roelen BAJ, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, et al. Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist. Journal of Experimental Medicine. 2004;199(6):805-14.
van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, et al. Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover. Journal of Bone and Mineral Research. 2011;26(12):2804-11.
Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Annals of internal medicine. 2013;158(11):825-30.
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European heart journal. 2018;39(33):3021-104.
Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H, et al. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab. 2014;99(10):E1854-61.
Abdallah E, Sherif N, Mosbah O, Metwally A, Abd ElAzim I, Mahmoud O, et al. The Relationship between Serum Sclerostin Levels and Bone Mineral Disorders and Vascular Calcification in Hemodialysis Patients. Open Access Macedonian Journal of Medical Sciences. 2021;9(B):1664-71.
Piec I, Washbourne C, Tang J, Fisher E, Greeves J, Jackson S, et al. How Accurate is Your Sclerostin Measurement? Comparison Between Three Commercially Available Sclerostin ELISA Kits. Calcified tissue international. 2016;98(6):546-55.
Maré A, Verhulst A, Cavalier E, Delanaye P, Behets GJ, Meijers B, et al. Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease. Journal of clinical medicine. 2019;8(12).
Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D. The relation between renal function and serum sclerostin in adult patients with CKD. Clinical journal of the American Society of Nephrology : CJASN. 2013;8(5):819-23.
Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab. 2014;99(1):248-55.
Roforth MM, Fujita K, McGregor UI, Kirmani S, McCready LK, Peterson JM, et al. Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone. 2014;59:1-6.
Sabbagh Y, Graciolli FG, O’Brien S, Tang W, dos Reis LM, Ryan S, et al. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. 2012;27(8):1757-72.
McGregor U, Hoey K, Amin S, McCready L, Achenbach S, Riggs B, et al. Relation of Age, Gender, and Bone Mass to Circulating Sclerostin Levels in Women and Men. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2011;26:373-9.
Kirmani S, Amin S, McCready LK, Atkinson EJ, Melton LJ, Müller R, et al. Sclerostin levels during growth in children. Osteoporosis International. 2012;23(3):1123-30.
Xu Y, Gao C, He J, Gu W, Yi C, Chen B, et al. Sclerostin and Its Associations With Bone Metabolism Markers and Sex Hormones in Healthy Community-Dwelling Elderly Individuals and Adolescents. 2020;Volume 8 - 2020.
Skrzypczyk P, Ofiara A, Szyszka M, Stelmaszczyk-Emmel A, Górska E, Pańczyk-Tomaszewska M. Serum Sclerostin Is Associated with Peripheral and Central Systolic Blood Pressure in Pediatric Patients with Primary Hypertension. Journal of clinical medicine. 2021;10(16).
El sebaie Mh, arafat ma, fawzy ms, salem im. The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes %J Zagazig University Medical Journal. 2021;27(1):58-69.